UNSPSC 51422416: Medrysone

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D2UFC189XF, chemically known as 11beta-hydroxy-6alpha-methylpregn-4-ene-3,20-dione but generally known as medrysone, which bears US NIH Compound Identifier 4043. European Medicines Agency schedules Medrysone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08701MIG. The term MEDRYSONE is an International Non-Proprietary Name.

UNSPSC 51422416 Medrysone is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and drug-management systems procured by health agencies and counties to support community health and pharmacy benefit programs. The code encompasses both branded pharmaceuticals and related ancillary products such as drug deactivation systems and naloxone kits. Issuing bodies include county health departments and state health and human services agencies; Seminole County, Florida and the Texas Health and Human Services Commission appear as recent active buyers. Work solicited ranges from direct product procurement with quarterly delivery schedules to exploratory vendor-capability assessments for direct-to-manufacturer pharmacy contracting models that bypass traditional pharmacy benefit managers and group purchasing organizations.

Recent activity spans Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a July 26, 2023 response deadline, requiring quarterly deliveries to the Seminole County Community Health Building and vendor-funded shipping. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, soliciting vendor information about direct-to-manufacturer prescription fulfillment capabilities and capacity to support self-insured health plans and state agencies outside traditional pharmacy benefit manager and group purchasing organization channels, with no formal award or budget identified at the RFI stage.